KEGG   DRUG: Brazikumab
Entry
D10912                      Drug                                   
Name
Brazikumab (USAN/INN)
Sequence
(Heavy chain)
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV IWYDGSNEYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDR GYTSSWYPDA FDIWGQGTMV
TVSSASTKGP SVFPLAPCSR STSESTAALG CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV
LQSSGLYSLS SVVTVPSSNF GTQTYTCNVD HKPSNTKVDK TVERKCCVEC PPCPAPPVAG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVQFNW YVDGVEVHNA KTKPREEQFN
STFRVVSVLT VVHQDWLNGK EYKCKVSNKG LPAPIEKTIS KTKGQPREPQ VYTLPPSREE
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPM LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
(Light chain)
QSVLTQPPSV SGAPGQRVTI SCTGSSSNTG AGYDVHWYQQ VPGTAPKLLI YGSGNRPSGV
PDRFSGSKSG TSASLAITGL QAEDEADYYC QSYDSSLSGW VFGGGTRLTV LGQPKAAPSV
TLFPPSSEEL QANKATLVCL ISDFYPGAVT VAWKADSSPV KAGVETTTPS KQSNNKYAAS
SYLSLTPEQW KSHRSYSCQV THEGSTVEKT VAPTECS
(Disulfide bridge: H22-H96, H138-L216, H151-H207, H226-H'226, H227-H'227, H230-H'230, H233-H'233, H264-H324, H370-H428, H'22-H'96, H'151-H'207, H'370-H'428, L22-L90, L139-L198, L'22-L'90, L'139-L'198)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Efficacy
Anti-inflammatory, Anti-IL-23 antibody
  Type
Monoclonal antibody
Comment
Treatment of Crohn's disease
Target
IL23A [HSA:51561] [KO:K05426]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
Brite
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D10912  Brazikumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL23A
     D10912  Brazikumab (USAN/INN)
Other DBs
CAS: 1610353-18-8
PubChem: 342581769
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system